Log In
Print this Print this

Jublia, efinaconazole (IDP-108, KP-103)

  Manage Alerts
Collapse Summary General Information
Company Kaken Pharmaceutical Co. Ltd.
DescriptionTopical triazole antifungal
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationOnychomycosis
Indication DetailsTreat mild to moderate onychomycosis; Treat onychomycosis of the toenails
Regulatory Designation U.S. - Undisclosed Review (Treat onychomycosis of the toenails);
U.S. - Undisclosed Review (Treat mild to moderate onychomycosis);
Canada - Standard Review (Treat mild to moderate onychomycosis)
PartnerValeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today